103440-95-5

Basic information

• Product Name: 4-ETHYL-3-NITROBENZOIC ACID
• Synonyms: 4-ETHYL-3-NITROBENZOIC ACID;3-Nitro-4-ethylbenzoic acid;4-ETHYL-3-NITROBENZOIC ACID, 98+%;3,4-4-Ethyl-3-nitrobenzoic acid;Benzoic acid,4-ethyl-3-nitro-
• CAS NO: 103440-95-5
• Molecular Formula: C₉H₉NO₄
• Molecular Weight: 195.17
• Mol File: 103440-95-5.mol

Chemical Properties

• Melting Point: 157.5-158.3 °C
• Boiling Point: 336℃
• Flash Point: 148℃
• Appearance: white crystal powder
• Density: 1.331
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.587
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3?+-.0.10(Predicted)
• CAS DataBase Reference: 4-ETHYL-3-NITROBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-ETHYL-3-NITROBENZOIC ACID(103440-95-5)
• EPA Substance Registry System: 4-ETHYL-3-NITROBENZOIC ACID(103440-95-5)

Safety Data

• Hazardous Substances Data: 103440-95-5(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
4-Ethyl-3-nitrobenzoic acid is used as a key intermediate in the synthesis of various organic compounds due to its enhanced reactivity from the nitro group.
Used in Dye Manufacturing:
4-Ethyl-3-nitrobenzoic acid is used as a precursor in the production of dyes, where its reactivity and structural components contribute to the formation of the desired colorants.
Used in Pharmaceutical Industry:
4-Ethyl-3-nitrobenzoic acid is used as a building block in the development of pharmaceuticals, where its reactivity allows for the creation of new drug molecules with potential therapeutic applications.
Used in Resin Production:
4-Ethyl-3-nitrobenzoic acid is used in the manufacturing of resins, where its structural components and reactivity contribute to the formation of polymers with specific properties for various applications.

InChI:InChI=1/C9H9NO4/c1-2-6-3-4-7(9(11)12)5-8(6)10(13)14/h3-5H,2H2,1H3,(H,11,12)

Upstream product

• 4748-80-5 4-ethyl-3-nitro-benzaldehyde 
• 619-64-7 p-ethylbenzoic acid 

Downstream Products

• 79481-75-7 4-acetyl-3-nitrobenzoic acid 
• 1018785-48-2 ethyl-4-ethyl-3-nitrobenzoate 
• 24812-93-9 3-amino-4-ethylbenzoic acid methyl ester 
• 1449668-98-7 C₁₇H₁₈N₄O₂ 
• 1039151-67-1 4-(1-bromoethyl)-3-nitrobenzoic acid methyl ester 
• 1619260-96-6 methyl 4-(1-methoxyethyl)-3-nitrobenzoate 
• 1619260-97-7 4-(1-methoxyethyl)-3-nitrobenzoic acid 
• 1619260-95-5 2,5-dioxopyrrolidin-1-yl 4-(1-methoxyethyl)-3-nitrobenzoate 
• 51885-79-1 4-ethyl-3-nitro-benzoic acid methyl ester 
• 868211-93-2 methyl 4-ethyl-3-fluorobenzoate 
• 1427395-09-2 (3-chloro-4-ethylphenyl)methanol 
• 1081551-72-5 methyl 3-chloro-4-ethylbenzoate 
• 201286-95-5 6-(methoxycarbonyl)-3-methyl-1H-indazole 
• 1581701-05-4 3-amino-4-ethyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide 

Relevant articles and documents

Ionic tags for synthesis of oligoribonucleotides

The invention relates to the chemical synthesis of oligonucleotides, e.g., oligoribonucleotides. In another aspect, the invention relates to compounds of formula (II) processes for making these compounds, and the use thereof in the chemical synthesis of o

Design and synthesis of a novel series of orally active, selective somatostatin receptor 2 agonists for the treatment of type 2 diabetes

The discovery of a novel series of β-methyltryptophan (β MeTrp) derivatives as selective and orally active non-peptide somatostatin receptor 2 (SSTR2) agonists for the treatment of Type 2 diabetes is described. In our previous research, Compound A, β-MeTr

Synthetic, structural mimetics of the β-hairpin flap of HIV-1 protease inhibit enzyme function

Small-molecule mimetics of the β-hairpin flap of HIV-1 protease (HIV-1 PR) were designed based on a 1,4-benzodiazepine scaffold as a strategy to interfere with the flap-flap protein-protein interaction, which functions as a gated mechanism to control acce

BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER

The present invention is directed to benzamide derivatives, pharmaceutical compositions containing them, and their use as FASN inhibitors, in for example, the treatment of cancer, obesity related disorders, liver related disorders and viral infections. Such compounds are represented by formula (I) as follows: wherein R1, R2, R3, R4, R5, m, n, (II) and (III) are defined herein.

GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a novel compound having GPR40 receptor agonist activity that promotes insulin secretion and inhibits blood sugar rise after glucose loading, and is thereby useful for the treatment of diabetes and complications thereof, the preparation method thereof and pharmaceutical composition containing them as an active ingredient.

HISTONE DEMETHYLASE INHIBITORS

Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

High-yielding and photolabile approaches to the covalent attachment of biomolecules to surfaces via hydrazone chemistry

The development of strategies to couple biomolecules covalently to surfaces is necessary for constructing sensing arrays for biological and biomedical applications. One attractive conjugation reaction is hydrazone formation - the reaction of a hydrazine w

IMIDAZO [4, 5 -C] PYRIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, wherein R1 and Cy are as disclosed herein. These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.

In vitro and in vivo uncaging and bioluminescence imaging by using photocaged upconversion nanoparticles

Trading up: A bioimaging system that is based on caged D-luciferin/ upconversion nanoparticle conjugate has been developed. The nanoparticles upconvert near-infrared light into UV light, which triggers the photorelease of D-luciferin (see scheme) and lead

PIPERIDINE DERIVATIVES FOR THE TREATMENT OF OBESITY

A compound of formula (I) or a pharmaceutically acceptable salt thereof, processes for preparing such compounds, their use as Fatty Acid Synthase inhibitors, methods for their therapeutic use, particularly in the treatment of obesity, diabetes mellitus, c